GSK’s Belantamab Mafodotin Receives FDA’s Priority Review for Relapsed or Refractory Multiple Myeloma

 GSK’s Belantamab Mafodotin Receives FDA’s Priority Review for Relapsed or Refractory Multiple Myeloma

GSK’s Belantamab Mafodotin Receives FDA’s Priority Review for Relapsed or Refractory Multiple Myeloma

Shots:

  • The PR status is based on P-II DREAMM-2 study assessing two doses of Belantamab Mafodotin (GSK2857916) in patients with r/r MM who are refractory to a proteasome inhibitor and an immunomodulatory agent with failed prior treatment with an anti-CD38 antibody
  • In 2017, the US FDA has granted the BT designation to therapy. Following its approval. It will be the first anti-BCMA therapy available to patients with MM
  • Belantamab mafodotin is an investigational anti-BMCA mAb conjugated to the cytotoxic agent auristatin F via a non-cleavable linker and is developed utilizing POTELLIGENT technology licensed from BioWa

Click here ­to­ read full press release/ article | Ref: GSK | Image: Reuter India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post